---
title: "Faeth Therapeutics CFO Brian C. Stephenson files initial beneficial ownership statement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290611234.md"
description: "Faeth Therapeutics CFO Brian C. Stephenson filed an initial beneficial ownership statement via EDGAR on June 23, 2026. The report discloses a stock option for 166,435 shares with an exercise price of $29.37, expiring on March 10, 2036."
datetime: "2026-06-23T21:22:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290611234.md)
  - [en](https://longbridge.com/en/news/290611234.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290611234.md)
generator: "portal-rs"
---

# Faeth Therapeutics CFO Brian C. Stephenson files initial beneficial ownership statement

-   Faeth Therapeutics CFO Brian C. Stephenson filed an initial ownership report showing a stock option for 166,435 shares at $29.37, expiring March 10, 2036. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001780030-26-000003), on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)

## Related News & Research

- [Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FTH Stock News](https://longbridge.com/en/news/297318443.md)
- [Faeth Therapeutics files initial beneficial ownership statement for Khosla Ventures VI, L.P](https://longbridge.com/en/news/294108113.md)
- [Palvella Therapeutics director Christopher P. Kiritsy disposes of 313 common shares for $49,141](https://longbridge.com/en/news/298071393.md)
- [Acrivon Therapeutics files Form 3 for Chief Business Officer Michaela Levin](https://longbridge.com/en/news/297826865.md)
- [Abeona Therapeutics director Mark Alvino disposes of 15,000 common shares worth $87,966](https://longbridge.com/en/news/297702333.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**